Execs named, Williams DARTs in as CEO
This article was originally published in Scrip
DART Therapeutics which is focused on developing therapies for Duchenne muscular dystrophy, has formed its executive team. Co-Founder and executive chairman Eugene Williams transitions to a full-time role as CEO, and Dr Ernest Bush joins as CSO. DART also added Dr Elliot Goldstein as chief medical officer and Cabot Brown as chief financial officer.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.